A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
M.D. Anderson Cancer Center
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Eli Lilly and Company
Hoffmann-La Roche
M.D. Anderson Cancer Center
AstraZeneca
Seagen Inc.
University of Kansas Medical Center
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
University of Southern California
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Shanghai Zhongshan Hospital
TCR2 Therapeutics
TCR2 Therapeutics
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Toray Industries, Inc
Eli Lilly and Company
Lisata Therapeutics, Inc.
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
Compass Therapeutics
OHSU Knight Cancer Institute
Shanghai Zhongshan Hospital
Universitätsklinikum Hamburg-Eppendorf
SOLTI Breast Cancer Research Group
Asan Medical Center
Shanghai Zhongshan Hospital
Qilu Hospital of Shandong University
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Soul Medicine Institute
The First People's Hospital of Changzhou